Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 254 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $84.10, for a total value of $21,361.40. Following the completion of the transaction, the president now directly owns 1,442,357 shares in the company, valued at approximately $121,302,223.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Stephen Hoge also recently made the following trade(s):
- On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
- On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00.
- On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The shares were sold at an average price of $144.50, for a total transaction of $49,274.50.
Moderna Stock Performance
Shares of MRNA opened at $82.25 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a 50-day simple moving average of $118.88 and a two-hundred day simple moving average of $114.11. The firm has a market capitalization of $31.52 billion, a PE ratio of -5.25 and a beta of 1.67.
Analyst Ratings Changes
Several analysts have issued reports on MRNA shares. Piper Sandler restated an “overweight” rating and set a $157.00 price target (down from $214.00) on shares of Moderna in a research report on Friday, August 2nd. UBS Group upped their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. The Goldman Sachs Group cut their price target on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Evercore ISI restated an “in-line” rating and set a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Finally, Canaccord Genuity Group upped their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $124.21.
Read Our Latest Report on Moderna
Institutional Trading of Moderna
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the second quarter valued at approximately $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna during the fourth quarter valued at approximately $27,000. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna during the first quarter valued at approximately $32,000. Finally, Family Firm Inc. bought a new stake in shares of Moderna during the second quarter valued at approximately $33,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- Transportation Stocks Investing
- 3 High-Potential Stocks Analysts Say Could Soar
- Financial Services Stocks Investing
- Brinker International’s Price Dip is an Appetizing Entry Point
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Stocks That Could Beat the September Blues
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.